✦ LIBER ✦

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy

✍ Scribed by Jana l. Antohe; Androniki Bili; Jennifer A. Sartorius; H. Lester Kirchner; Stephanie J. Morris; Sorina Dancea; Mary Chester M. Wasko

Publisher: Wiley (John Wiley & Sons)
Year: 2012
Tongue: English
Weight: 108 KB
Volume: 64
Category: Article
ISSN: 2151-464X
DOI: 10.1002/acr.20657

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Modulation of CD28 expression with anti–

Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis

✍ Ewa Bryl; Abbe N. Vallejo; Eric L. Matteson; Jacek M. Witkowski; Cornelia M. Wey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Anti-tumor necrosis factor α therapy in

Anti-tumor necrosis factor α therapy in rheumatoid arthritis: Hitting two birds with one stone?

✍ Warrington, Kenneth J. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Rheumatoid arthritis risk allele PTPRC i

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti–tumor necrosis factor α therapy

✍ Jing Cui; Saedis Saevarsdottir; Brian Thomson; Leonid Padyukov; Annette H. M. va 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 1 views

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer

✍ Deborah P. M. Symmons; Alan J. Silman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Antiangiogenic effects of anti–tumor nec

Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis

✍ Juan D. Cañete; José L. Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

## Abstract ## Objective Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to ana